

**UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION**

ELI LILLY AND COMPANY,

Plaintiff,

v.

HOSPIRA, INC.,

Defendant.

No. 1:16-cv-3460-TWP-MPB


AMENDED FINAL JUDGMENT


Plaintiff Eli Lilly and Company (“Lilly”), by counsel, having filed its Unopposed Motion to Amend Final Judgment, and the Court having considered the Motion now finds that it should be granted. Pursuant to the Court’s ruling on summary judgment, final judgment is hereby entered as follows:

1. The filing of NDA No. 208746 infringed at least claims 9, 10, 12, 13, 14, 15, 18, 19, 21, and 22 of U.S. Patent No. 7,772,209, and those claims have not been proved invalid.
2. Pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of any product that is the subject of NDA No. 208746 shall be not earlier than the latest date of expiration of U.S. Patent No. 7,772,209, including any period of pediatric exclusivity.
3. JUDGMENT IS ENTERED in favor of Lilly and against Hospira, Inc.

Date: 6/27/2018

Laura A. Briggs, Clerk

BY: 
Deputy Clerk, U. S. District Court


Hon. Tanya Walton Pratt, Judge
United States District Court
Southern District of Indiana